Gilead’s Veklury (remdesivir) Receives WHO’s Recommendation for the Treatment of COVID-19
Shots:
- The WHO recommends Veklury for the treatment of sev. COVID-19 & also in patients with non-severe COVID-19 who are at the highest risk of hospitalization
- The recommendation was based on a WHO-sponsored (SOLIDARITY) study which showed a 17% reduction in relative risk of death or progression & 13% in mortality for patients requiring supplemental oxygen at baseline over SoC and not requiring mechanical ventilation & had no significant effect on patients with COVID-19
- Veklury was approved or authorized for temporary use in ~50 countries globally & has been approved in the US for pediatric patients aged ~28 days who are hospitalized or not hospitalized & at high risk of progression to sev. COVID-19
Ref: Businesswire| Image: Gilead
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
